Evidence map›Paper›PMID 39201235›Full record

ArticleHealthcare (Basel, Switzerland)2024

Impact of the COVID-19 Pandemic on the Diagnosis of Malignant Neoplasia of the Bronchus and Lung in the Burgos Region.

Gustavo Gutiérrez Herrero, Sandra Núñez-Rodríguez, Sergio Álvarez-Pardo, Jessica Fernández-Solana, Carla Collazo-Riobó, Álvaro García-Bustillo, Mirian Santamaría-Peláez, Jerónimo J González-Bernal, Josefa González-Santos

Abstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gustavo Gutiérrez HerreroPulmonology Unit, Burgos University Hospital, 09006 Burgos, Spain.
Sandra Núñez-RodríguezDepartment of Health Sciences, University of Burgos, 09001 Burgos, Spain.ORCID 0009-0005-5171-6871
Sergio Álvarez-PardoFaculty of Health Science, University Isabel I, 09003 Burgos, Spain.
Jessica Fernández-SolanaDepartment of Health Sciences, University of Burgos, 09001 Burgos, Spain.ORCID 0000-0001-9937-7753
Carla Collazo-RiobóDepartment of Health Sciences, University of Burgos, 09001 Burgos, Spain.ORCID 0000-0002-4365-3138
Álvaro García-BustilloDepartment of Health Sciences, University of Burgos, 09001 Burgos, Spain.
Mirian Santamaría-PeláezDepartment of Health Sciences, University of Burgos, 09001 Burgos, Spain.ORCID 0000-0002-4255-7355
Jerónimo J González-BernalDepartment of Health Sciences, University of Burgos, 09001 Burgos, Spain.ORCID 0000-0002-7298-9060
Josefa González-SantosDepartment of Health Sciences, University of Burgos, 09001 Burgos, Spain.ORCID 0000-0003-3089-7018

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo retrospectively analyze the impact of the COVID-19 pandemic on the diagnosis, mortality rate, and survival period of malignant bronchial and lung neoplasms in the Burgos region, with the aim of promoting the development of strategies to improve cancer care management during health crises, highlighting the importance of non-pharmacological approaches to mitigate the negative impacts of future pandemics on lung cancer patients.

methodsThis retrospective, longitudinal, single-center study was conducted in Burgos from 2019 to 2021. Participants included all patients diagnosed with malignant bronchial and lung neoplasms by the Pneumology unit of Complejo Asistencial Universitario de Burgos during the year immediately before and the year immediately after 31 March 2020, the official start date of the pandemic. Inclusion criteria encompassed patients diagnosed through histological or clinicoradiological methods, who provided informed consent. Data were systematically gathered using a specific template that included demographic information, disease stage, death, and survival time. Statistical analysis involved descriptive methods, ANOVA, and chi-square tests to assess differences in survival time and associations between categorical variables.

resultsThe results reveal a decrease in the number of patients diagnosed during the pandemic period (154 vs. 105), which could indicate delays in detection. However, there were no significant differences between the two periods, in which more than 60% of cases were detected in stage IV, being incompatible with survival. Although fewer patients died during the pandemic than expected (

conclusionsUnderstanding these changes can support both medical strategies and non-pharmacological therapies to improve cancer care management during health crises, thus contributing to the optimization of public health.

Indexed as

COVID-19diagnosishealthcarelifestylemalignant lung neoplasianon-communicable diseasessurvival

Identifiers

PMID39201235
PMCPMC11353311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.